RoyMitchelFleischmannMD

PubMed

• 1 citations
  Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.
  Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Thomas W J Huizinga, Gustavo Citera, Clifton O Bingham 3rd, Subhashis Banerjee, Benjamin P Soule, Marleen Nys, Sean E Conn...> ;Rheumatology and Therapy. 2023 Jun 1
• Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
  Gerd R Burmester, Vibeke Strand, Alan J Kivitz, Chih-Chi Hu, Sheldon Wang, Hubert van Hoogstraten, Gabriella L Klier, Roy Fleischmann> ;Rheumatology. 2023 Feb 2
• Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.
  Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey...> ;Rheumatology and Therapy. 2023 Jun 1
• Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
  Roy Fleischmann, Boulos Haraoui, Maya H Buch, David Gold, Gosford Sawyerr, Harry Shi, Annette Diehl, Kristen Lee> ;Rheumatology and Therapy. 2023 Apr 1
• Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated pro...
  Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O ...> ;RMD Open. 2022 Dec 1
• Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.
  Kurt de Vlam, Philip J Mease, Andrew G Bushmakin, Roy Fleischmann, Alexis Ogdie, Valderilio F Azevedo, Joseph F Merola, John Woolcott, Joseph C Cappelleri, Lara Fallon...> ;Rheumatology and Therapy. 2022 Oct 1
• 1 citations
  Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-...
  Eduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, Daniel Aletaha, Peter C Taylor, In-Ho Song, Tim Shaw, Yanna Song, Ryan DeMasi, Mira Ali, Roy Fleischmann> ;Rheumatology. 2023 May 2
• Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
  Roy M Fleischmann, Amy E Bock, Wuyan Zhang, Charles M Godfrey, Ivana Vranic, Carol Cronenberger, Eva Dokoupilová> ;Rheumatology and Therapy. 2022 Jun 1
• Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
  Roy Fleischmann, Kyle Hayes, Sung-Woo Ahn, George J Wan, Mary Panaccio, Daniel Karlsson, Daniel E Furst> ;Rheumatology and Therapy. 2022 Apr 1
• 2 citations
  Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
  Omar Jabado, Michael A Maldonado, Michael Schiff, Michael E Weinblatt, Roy Fleischmann, William H Robinson, Aiqing He, Vishal Patel, Alex Greenfield, Jasmine Saini, Da...> ;Rheumatology and Therapy. 2022 Apr 1
• Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid A...
  Roy Fleischmann, Kyle Hayes, Sung-Woo Ahn, George J Wan, Mary P Panaccio, Daniel Karlsson, Daniel E Furst> ;Rheumatology and Therapy. 2022 Apr 1
• 6 citations
  Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.
  Peter C Taylor, Rieke Alten, Jose María Álvaro Gracia, Yuko Kaneko, Chad Walls, Amanda Quebe, Bochao Jia, Natalia Bello, Jorge Ross Terres, Roy Fleischmann> ;RMD Open. 2022 Mar 1
• 24 citations
  Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
  Roy Fleischmann, Eduardo Mysler, Louis Bessette, Charles G Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song> ;RMD Open. 2022 Feb 1
• 2 citations
  Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
  Philip G. Conaghan, Stanley Cohen, Gerd R Burmester, Eduardo Mysler, Peter Nash, Yoshiya Tanaka, William F. C. Rigby, Jayeshkumar Patel, T. Shaw, Keith A. Betts, Panka...> ;Rheumatology and Therapy. 2021 Nov 23
• 3 citations
  Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimum...
  Roy Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten> ;Arthritis Research & Therapy. 2021 Sep 25
• Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.
  Roy Fleischmann> ;Clinical Rheumatology. 2021 Sep 24
• 5 citations
  Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
  Désirée van der Heijde, Cynthia E. Kartman, Li Xie, Scott Beattie, Douglas E Schlichting, Daojun Mo, Patrick Durez, Yoshiya Tanaka, Roy Fleischmann> ;The Journal of Rheumatology. 2021 Sep 15
• 8 citations
  Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study.
  Victoria P. Werth, Roy Fleischmann, Michael Robern, Zahi Touma, Iyabode Tiamiyu, Oksana Gurtovaya, Alena Pechonkina, Afsaneh Mozaffarian, Bryan R. Downie, Franziska Ma...> ;Rheumatology. 2021 Sep 8
• Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus ...
  Tsutomu Takeuchi, Roy Fleischmann, Noriko Iikuni, Harry Shi, Koshika Soma, Jerome Paulissen, Tomohiro Hirose, Josef S Smolen> ;Arthritis Research & Therapy. 2021 Aug 24
• 3 citations
  Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.
  Kurt de Vlam, Alexis Ogdie, Andrew G. Bushmakin, Joseph C. Cappelleri, Roy Fleischmann, Peter C. Taylor, Valderilio Azevedo, Lara Fallon, John Woolcott, Philip J. Mease> ;RMD Open. 2021 Jul 1
• 19 citations
  A Decade of Jakinibs: what have we learned and what may be the future.
  Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O'Shea> ;Arthritis & Rheumatology. 2021 Jun 27
• 5 citations
  Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies.
  Mark C. Genovese, Patrick Durez, Roy Fleischmann, Yoshiya Tanaka, Daniel E. Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi> ;European Journal of Rheumatology. 2021 Jun 4
• 10 citations
  Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
  Roy Fleischmann, Mark C. Genovese, Karina Maslova, H. Leher, A. Praestgaard, Gerd R Burmester> ;Rheumatology. 2021 Nov 3
• The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal.
  Roy Fleischmann> ;The Journal of Rheumatology. 2021 Apr 15
• 4 citations
  Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52...
  Roy Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten> ;RMD Open. 2021 Apr 1
• Join now to see all

Lectures

• A Comparative Clinical Study of PF-06410293, a Candidate Adalimumab Biosimilar, and Adalimumab Reference Product (Humira®) in the Treatment of Active Rheumatoid Arthritis 
  Rheumatology Winter Clinical Symposium, Maui, Hawaii - 2/6/2013